MedTest Dx

MedTest Dx provides decentralized testing technologies for clinical testing. With a focus on screening instruments, reagent manufacturing, and LC/MS toxicology confirmation products, the company is a global leader in biotechnology and healthcare. Established in 2011 and headquartered in the United States, MedTest Dx has garnered recognition for its scientific and regulatory expertise. The Private Equity Round investment on 19 May 2011 involved the Enhanced Equity Fund and James White, signifying early support and confidence in the company's vision.

MedTest Dx's commitment to understanding customer needs drives its innovation, offering reliable and scalable instrumentation for budget-constrained clients. The company's focus on customer advocacy positions it as a partner of choice for addressing daily challenges in clinical testing. Through its impeccable reputation in chemistry, toxicology, and hematology, MedTest Dx continually seeks to deliver optimal solutions, solidifying its role in driving advancements in decentralized clinical testing.